60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals Inc(SXTP)股票分析

$0.950

-0.066 (-6.91%)收盘时

Loading chart…
High
1.050
Open
1.030
VWAP
0.97
Vol
105.16K
Mkt Cap
3.28M
Low
0.900
Amount
101.63K
EV/EBITDA, TTM
0.00

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

估值指标

The current forward P/E ratio for 60 Degrees Pharmaceuticals Inc (SXTP) is -0.14, compared to its 5-year average forward P/E of -0.88.

Forward P/E

Fair
5Y Average P/E
-0.88
Current P/E
-0.14
高估
-0.02
低估
-1.74

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Fair
5Y Average P/S
4.84
Current P/S
1.47
高估
10.59
低估
-0.91

Alphio AI Price Scenarios for SXTP

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SXTP

$4.69

情景价格

B

Base

Base · 50%SXTP

$4.56

情景价格

B

Bear

Bear · 25%SXTP

$4.10

情景价格

事件时间线

2026-07-30 (ET)

14:30:00

60 Degrees Pharmaceuticals Issues 574,713 Shares, Raises Approximately $1 Million

2026-07-29 (ET)

17:30:00

60 Degrees Pharmaceuticals Completes Patient Enrollment for Severe Babesiosis Clinical Trial

2026-07-08 (ET)

09:30:00

60 Degrees Pharmaceuticals Enters Exclusive Agreement with Florida State University

2026-07-01 (ET)

08:30:00

60 Degrees Pharmaceuticals Recommended to Continue B-Free Study

2026-06-11 (ET)

09:00:00

60 Degrees Pharmaceuticals Signs Patent Licensing Agreement with Florida State University

资讯

SXTP FAQ — answered by Alphio AI

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始